suzetrigine
Trade name: Journavx
Small moleculeapproved
Approved
Jan 30, 2025
Clinical trial activity
32 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
12
Phase 3
7
Phase 4
6
Earliest trial started Jul 19, 2021 (NCT04977336)
Timeline
Indications
Approved for
Studied for
- Acute Pain · Phase 4
- Analgesia · Phase 3
- Analgesics, Opioid · Phase 3
- Arthroplasty · Phase 3
- Arthroplasty, Replacement, Hip · Phase 3
- Carcinoma, Hepatocellular · Early Phase 1
- Diabetes Mellitus · Phase 2
- General Surgery · Phase 3
- Osteoarthritis · Phase 4
- Pain Management · Phase 3
- Pain Threshold · Early Phase 1
- Postoperative Pain · Phase 2
- Randomized Controlled Trial · Phase 3
- Rib Fractures · Phase 4
Mechanism of action
SCN10A inhibitor
Approval history
- approvedPriority reviewJan 30, 2025
Chemistry & pharmacology
Loading structure…
SMILES
COc1c([C@H]2[C@H](C(=O)Nc3ccnc(C(N)=O)c3)O[C@@](C)(C(F)(F)F)[C@H]2C)ccc(F)c1F- Mol. weight
- 473.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314487 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07257133 | Phase 4 | Mar 31, 2026 | Mayo Clinic |
| NCT07283770 | Phase 1 | Dec 9, 2025 | Vertex |
| NCT07219888 | Phase 4 | Dec 1, 2025 | University of Louisville |
| NCT07226700 | Phase 3 | Nov 30, 2025 | Rockefeller University |
| NCT07231419 | Phase 3 | Nov 17, 2025 | Vertex |
| NCT07145346 | Phase 4 | Nov 13, 2025 | University of California, Irvine |
| NCT07195669 | Phase 4 | Oct 1, 2025 | Louisiana State University |
| NCT07201064 | Early Phase 1 (Phase 1) | Sep 25, 2025 | Guangdong ProCapZoom Biosciences Co., Ltd. |
| NCT06972212 | Early Phase 1 (Phase 1) | Jun 4, 2025 | Latigo Biotherapeutics |
| NCT06887959 | Phase 4 | Mar 27, 2025 | Vertex |
| NCT06887972 | Phase 4 | Mar 21, 2025 | Vertex |
| NCT06834009 | Phase 1 | Mar 10, 2025 | Vertex |
| NCT06820307 | Phase 1 | Feb 25, 2025 | Vertex |
| NCT06696443 | Phase 3 | Dec 31, 2024 | Vertex |
| NCT06774625 | Phase 2 | Dec 19, 2024 | Latigo Biotherapeutics |
| NCT06628908 | Phase 3 | Oct 1, 2024 | Vertex |
| NCT06420765 | Phase 1 | May 21, 2024 | Vertex |
| NCT06336096 | Phase 1 | Mar 28, 2024 | Vertex |
| NCT06176196 | Phase 2 | Dec 31, 2023 | Vertex |
| NCT05851157 | Phase 1 | May 3, 2023 | Vertex |
Showing 20 of 32 trials
Page 1 / 2
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 24 | 24 | 4 | 2021 |
| Latigo Biotherapeutics | For profit | 2 | 2 | 2 | 2024 |
| Guangdong ProCapZoom Biosciences Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Louisiana State University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Rockefeller University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of California, Irvine | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Louisville | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1